<DOC>
	<DOCNO>NCT01923402</DOCNO>
	<brief_summary>This study conduct develop biomarkers tobacco effect would indicate potential harm relate tobacco consumption . To gain good understand chronic effect tobacco consumption , cross-sectional clinical study enrol generally healthy , adult male consumer cigarette ( SMK ) , moist snuff ( MSC ) , tobacco product ( NTC ) .</brief_summary>
	<brief_title>Development Biomarkers Effect From Chronic Tobacco Usage</brief_title>
	<detailed_description>This single site , three-group ( healthy , adult male smoker ( SMK ) , moist snuff consumer ( MSC ) , non-tobacco consumer ( NTC ) , single-blind , cross-sectional study , include one overnight confinement study subject Test Visit ( Visit # 3 ) . No lifestyle change require , inclusive tobacco habit . In addition Screening Visit ( Visit # 1 ) , two visit ( Acceptance Visit [ Visit # 2 ] Test Visit [ Visit # 3 ] ) conduct clinical study site .</detailed_description>
	<criteria>1 . Males 35 60 year age , inclusive ; 2 . Met cohortspecific requirement follow : 1 . Smokers : Must exclusive full flavor ( FF ) ( &gt; 13 mg FTC [ Federal Trade Commission ] `` tar '' ) full flavor low `` tar '' ( FFLT ) ( 6.0 10.3 mg FTC `` tar '' ) smoker selfreported smoke least 10 cigarette daily least past three year prior screen whose expired carbon monoxide ( ECO ) 10 100 part per million ( ppm ) screening study checkin . Note : Subjects ECO 2 9 ppm may include upon joint review Sponsor Investigator . 2 . Moist Snuff Consumers : Must exclusive moist snuff consumer brand ( Copenhagen , Skoal , Grizzly , Kodiak , Timber Wolf , Longhorn , Red Man , etc . ) , style ( snuff cut , long cut , mid cut , fine cut , pouch ) flavor ( natural , straight , mint , wintergreen , etc . ) report use least two per week least past three year prior screen whose ECO 0 5 ppm screen study checkin . Note : Subjects ECO 6 10 ppm may include upon joint review Sponsor Investigator . 3 . NonTobacco Consumers : Must nonconsumers tobacco nicotinecontaining product least five year prior study screen whose ECO 0 5 ppm screen study checkin . Note : Subjects ECO 6 10 ppm may include upon joint review Sponsor Investigator . 3 . Subjects tobacco smoker : NOT intend quit smoking intend quit use moist snuff . `` Intent quit '' define plan quit attempt within month screening . 4 . All subject must meet American Red Cross Blood Donation Eligibility Guidelines ( 64 ) ( inclusive , limited , age , blood pressure , bleed condition , recent donation , weight ) generally healthy felt well restriction limitation activity . 5 . Weighed least 110 pound . 6 . Had hemoglobin &gt; /= 12.5 g/dL hematocrit &gt; /= 38 % . 7 . Tested negative drug abuse urine drug screen screen study checkin , unless subject able present proof correspond prescription concomitant medication . 8 . Performed negative breath alcohol test screening study checkin . 9 . Had negative urine cotinine test screening study checkin nontobacco consumer . 10 . Had positive urine cotinine test screening study checkin tobacco consumer . 11 . Subjects must , opinion Investigator , free clinically significant health problem , include oral health . 12 . Not take daily medication chronic medical condition deem clinically significant Investigator . 13 . Not regularly take creatine supplement . 14 . Not use aspirin ( related drug , aspirin prophylaxis 81 mg/day ) seven day prior study checkin . 15 . Tested negative Hepatitis B Surface Antigen ( HBsAg ) , negative Hepatitis C Antibody ( HCAb ) , negative Human Immunodeficiency Virus ( HIV ) screen . 16 . At least 60 day pass since subject 's last whole blood ( standard ) donation . 17 . Able comprehend willing sign Informed Consent Form ( ICF ) . 18 . Able read comprehend questionnaire English . Subjects meet follow criterion exclude study : 1 . Met cohort specific exclusion follow : 1 . Smokers : For three year prior study Day 1 , use tobacco nicotine contain product device FF FFLT tobaccoburning cigarette , include tobaccoheating cigarette , e cigarette , beedis , chew tobacco , dry snuff , moist snuff , snus , nicotine replacement therapy ( NRT ) ( e.g. , patch , gum , lozenge , inhaler , spray , etc. ) . NOTE : Subjects smoke &lt; 6 cigar past 12 month prior screen would NOT exclude . Subjects receive shortterm administration NRT temporary bridging treatment would NOT exclude . 2 . Moist Snuff Consumers : For three year prior study Day 1 , use tobacco nicotinecontaining product device moist snuff , include tobaccoburning cigarette , tobaccoheating cigarette , ecigarettes , beedis , cigar , pipe , chew tobacco , snus , dry snuff , NRT ( e.g. , patch , gum , lozenge , inhaler , spray , etc. ) . NOTE : Subjects receive shortterm administration NRT temporary bridging treatment would NOT exclude . 3 . Non Tobacco Consumers : For five year prior study Day 1 , use kind tobacco product use nontobacco nicotinecontaining product ( NRTs ) device ( e.g. , ecigarettes ) . 2 . Subjects tobacco consumer : express interest quit smoke use moist snuff ( define planning quit attempt within month screen ) . 3 . Subjects MSC user non tobacco consumer : ECO &gt; 5 ppm screen study checkin ( ECO 6 10 ppm may exclude base joint review Sponsor Investigator ) . 4 . Subjects smoker : ECO &lt; 10 ppm screen study checkin ( ECO 2 9 ppm may exclude base joint review Sponsor Investigator ) . 5 . Any chronic illness , opinion Investigator , unstable . 6 . A temperature 99.5° F. 7 . Poor peripheral venous access . 8 . Clinically uncontrolled hypertension ( &gt; /= 180 mmHg systolic &gt; /= 100 mmHg diastolic blood pressure ) . 9 . Diabetes mellitus ( either insulindependent noninsulin dependent ) . 10 . Blood sugar level &gt; 130 mg/dL minimum 8 hour fast request screen . 11 . Peak flow ≤ 70 % predicted average peak expiratory flow ( PEF ) age height . 12 . Clinical manifestation significant metabolic , hepatic , renal , hematological , pulmonary , cardiovascular , gastrointestinal , urological , neurological , psychiatric disorder . 13 . History presence abnormal electrocardiogram ( ECG ) , , Investigator 's opinion , clinically significant . 14 . History alcohol abuse illicit drug use within one year prior study entry . NOTE : Subjects selfreported drink less equal 14 serving alcoholic beverage per week ( 1 serve = 12 ounce beer , 6 ounce wine , 1 ounce liquor ) NOT exclude . 15 . Presence acute infection , without antibiotic treatment . 16 . Any history abnormal bleeding clot disorder , individual taking anticoagulant . 17 . Any history clot disorder Factor V take anticoagulant . 18 . Cancer treat successfully , less 5 year since completion treatment , skin cancer ( exclusionary melanoma ) . 19 . Squamous basal cell cancer skin NOT completely remove . 20 . History leukemia lymphoma , include Hodgkin 's disease cancer blood . 21 . Known tuberculosis . 22 . Sickle cell disease . 23 . Acquired Immune Deficiency Syndrome ( AIDS ) positive HIV antibody test . 24 . History illegal intravenous ( IV ) drug use . 25 . Required use concomitant medication exclude study . 26 . Less 12 month since blood transfusion another person United States ( unless `` autologous '' blood ) , exposure someone else 's blood . 27 . Less 6 month since diagnosis treatment significant heart murmur . 28 . Less 12 month since treatment syphilis gonorrhea complete . 29 . Less 60 day since participation investigational study receipt investigation drug product occur . 30 . Evidence visible oral cancer , find oral health examination screen visit .</criteria>
	<gender>Male</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Biomarkers</keyword>
	<keyword>Metabolic Profiling</keyword>
	<keyword>Metabolomics</keyword>
	<keyword>Tobacco</keyword>
	<keyword>Smokeless Tobacco</keyword>
	<keyword>Moist Snuff</keyword>
</DOC>